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Abstract Tenascin-C is an extracellular matrix protein with
growth-, invasion- and angiogenesis-promoting activities. Tenas-
cin-C is upregulated in breast carcinoma and stromal cells, and in
many other cell types during tumorigenesis. We demonstrate that
tenascin-C RNA expression is inhibited by 1,25-dihydroxyvita-
min D3 (1,25-D3) in a variety of mouse and human mammary
epithelial cell lines exhibiting normal or malignant phenotype. In
EpH4 cells, the inhibition is maximum 24 h after 1,25-D3
treatment and correlates with a dose-dependent reduction in the
synthesis of tenascin-C protein. Furthermore, 1,25-D3 also
abolishes the induction of tenascin-C by serum or the tumor
promoter 12-O-tetradecanoyl phorbol 13-acetate. The inhibition
of tenascin-C expression may be relevant for the anticancer
activity of 1,25-D3.
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1. Introduction
1,25-Dihydroxyvitamin D3 (1,25-D3), the most active me-
tabolite of vitamin D, has growth-inhibitory activities on cells
from a series of cancers including breast, prostate, melanoma,
sarcoma, pancreas, and renal cell carcinoma ([1^4] and refer-
ences therein). In addition, 1,25-D3 induces di¡erentiation of
leukemia cells [5]. In vivo, 1,25-D3 also inhibits tumor growth
in animal models [6,7]. 1,25-D3 and several analogues have
recently been shown to suppress DNA synthesis and the phos-
phorylation of retinoblastoma protein in breast cancer cells,
and to promote active cell death via apoptosis [4,8]. Most (80^
90%) primary human breast tumors express 1,25-D3 receptors,
a fact which seems to predict signi¢cantly longer disease-free
intervals [2]. In a human trial, a vitamin D analogue has been
shown to reduce by 50% the size of three out of 14 cutaneous
breast cancer metastases [9]. In line with these data, epidemio-
logical studies suggest a chemopreventive e¡ect of vitamin D
on the appearance of several types of cancer such as breast,
prostate, and colon [10,11].
Tenascin-C is the prototype of the tenascin family of ex-
tracellular matrix glycoproteins thought to exert multiple ef-
fects on cell morphology, di¡erentiation and physiology [12].
Tenascin-C is expressed at high levels during development,
but in adult life it is expressed only during speci¢c processes
such as wound healing, in£ammation and tumorigenesis. Ac-
tivities of tenascin-C include growth promotion, anti-adhesive
e¡ects favoring cell motility, immunosuppression, and induc-
tion of angiogenesis. Both epithelial and stromal cells express
tenascin-C in the mammary gland and breast tumors [13].
Tenascin-C expression seems to be inversely correlated with
the di¡erentiation of epithelial cells [14]. In fact, tenascin-C
has been found to inhibit extracellular matrix/prolactin-de-
pendent expression of the L-casein gene [15]. A correlation
has been reported between high levels of tenascin-C expres-
sion and the malignancy of a series of human tumors, includ-
ing breast and several other carcinomas [12,16,17]. Tenascin-C
expression has recently been found to indicate a poor prog-
nosis in human breast cancers [18]. Very importantly, tenas-
cin-C expression in the area of the invasion border has been
reported to be a strong predictor of distant breast cancer
metastasis [19].
Based on the e¡ects of 1,25-D3 and on the increasing rele-
vance proposed for tenascin-C in breast cancer, we have ex-
amined whether 1,25-D3 may regulate tenascin-C expression
in several normal and malignant mammary epithelial cell
lines.
2. Materials and methods
2.1. Materials
1,25-D3 was a kind gift from Productos Roche (Madrid, Spain). 12-
O-Tetradecanoyl phorbol 13-acetate (TPA), estradiol, and bovine se-
rum albumin (BSA) fraction V were from Sigma (St. Louis, MO,
USA). Dulbecco’s modi¢ed Eagle’s medium (DMEM) and RPMI
medium, fetal calf serum (FCS) and glutamine were all from Life
Technologies (Paisley, UK). Autoradiography ¢lms, Amplify, and
Promix used for protein labeling were from Amersham (London,
UK). Protein A-Sepharose was purchased to Pharmacia (Sweden),
and the rabbit polyclonal anti-human tenascin-C antibody used in
the immunoprecipitation assays was also from Life Technologies.
2.2. Cell culture
Previously described EpH4 cells [20], and MDA-MB-231 and
BT474 (American Type Culture Collection) mammary epithelial cells
were grown and maintained in DMEM supplemented with 10% FCS
and 1 mM glutamine. HC11 cells (a gift from Dr. N.E. Hynes, Frie-
drich Mieschner Institute, Switzerland) were grown in RPMI medium
with the same supplements. When indicated, serum was omitted and
replaced by 0.1 mg/ml BSA fraction V.
2.3. RNA preparation and Northern analysis
Puri¢cation of poly(A) RNA, Northern blotting and hybridiza-
tions were performed as described [21]. Filters were washed twice
for 30 min each in 1% SDS and 40 mM sodium phosphate, pH 7.2
at 65‡C. Membranes were exposed to Hyper¢lm MP ¢lms. Densito-
metric analysis was performed in a La Cie scanner connected to a
Macintosh IIci computer using Adobe Photoshop 2.0 and NIH Image
Programs. Tenascin-C probe was a 1540 bp fragment (positions 1532^
3072) from the mouse cDNA generously donated by Dr. P. Ekblom
(Uppsala University, Sweden). SGP-2/TRPM-2 probe was the full-
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length 1857 bp cDNA donated by Drs. M. Griswold and S.R. Syl-
vester (Washington State University, Seattle, WA, USA). A 1.1 kb
BamHI fragment of the pUC19-hsyn4 plasmid encoding the human
syndecan cDNA, donated by Drs. M. Mali and M. Jalkanen
(University of Turku, Finland), and a 1.1 kb EcoRI-SmaI of the
pSG5-hVitDR+ encoding the human vitamin D receptor cDNA, do-
nated by Dr. M. Zenke (Max-Delbruºck Center, Berlin, Germany),
were used.
2.4. Immunoprecipitation assays
Cells were grown to near con£uence in 60 mm diameter dishes and
treated or not with 1,25-D3 for 24 h. After washing with phosphate-
bu¡ered saline, cells were incubated for 30 min in methionine- and
cysteine-free, serum-free DMEM. They were then labeled for 3 h in
the same medium containing 0.1 mCi/ml Promix. 1,25-D3 was kept in
the medium during the labeling period. After labeling, cells were col-
lected in RIPA bu¡er (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1%
SDS, 1% NP-40, 0.5% sodium deoxycholate) and centrifuged at
200Ug for 10 min at 4‡C. Supernatants were incubated with rabbit
preimmune serum. Tenascin-C was immunoprecipitated by incubation
with an appropriate rabbit polyclonal anti-human tenascin-C anti-
body for 3 h at 4‡C. Immunoprecipitates were collected by incubation
with protein A-Sepharose for 30 min at 4‡C, washed four times with
RIPA bu¡er and analyzed by electrophoresis in 6% polyacrylamide
SDS gels followed by £uorography using Amplify.
3. Results
3.1. E¡ects of 1,25-D3 on tenascin-C RNA levels in EpH4 cells
First, we analyzed the e¡ects of 1,25-D3 on tenascin-C
RNA expression in EpH4 cells, a non-tumorigenic mouse
mammary cell line with normal epithelial phenotype [20,21].
Treatment for 24 h with 1,25-D3 caused a dose-dependent
reduction in tenascin-C RNA levels (a major band of 9.5 kb
and a minor band of 7.5 kb) in cells cultured in serum-free
medium (Fig. 1A,B). Doses as low as 1 nM 1,25-D3 resulted
in a reduction of tenascin-C RNA content greater than 2-fold,
while higher doses (10^1000 nM) led to a 6^8-fold reduction.
These doses of 1,25-D3 did not signi¢cantly inhibit DNA syn-
thesis nor cause cell death during the assay (not shown). Fur-
ther suggesting that the inhibition of tenascin-C is unrelated
to e¡ects on cell growth, we have observed that TGF-L causes
an increase in tenascin-C expression while displaying a potent
antimitogenic action on EpH4 cells (not shown). Also in line
with this, 1,25-D3 did not change the expression of SGP-2/
TRPM-2, a gene induced in a number of cell lines undergoing
apoptosis which has been reported to be induced by vitamin
D analogues [8] (Fig. 1A). Likewise, neither the RNA level of
the matrix proteoglycan syndecan nor that of the vitamin D
receptor (VDR) is a¡ected by 1,25-D3 (Fig. 1A). Next, we
examined the kinetics of the inhibitory action of 1,25-D3. A
reduction in tenascin-C RNA levels was already observed 8 h
after beginning the treatment, and was maximum 16 h later
(Fig. 1C). Since 1,25-D3 did not change the low transcrip-
tional rate of tenascin-C gene in run-on assays (not shown),
it is highly probable that the inhibitory e¡ect of 1,25-D3 is
a consequence of an e¡ect on the stability of tenascin-C
mRNA.
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Fig. 1. Inhibition of tenascin-C gene expression by 1,25-D3 in EpH4
cells. A: Dose-dependent regulation of tenascin-C gene expression
in 1,25-D3-treated EpH4 cells. Exponentially growing EpH4 cells
were changed to serum-free medium and treated with the indicated
concentrations of 1,25-D3 for 24 h. Poly(A) RNA (10 Wg/lane) was
analyzed by Northern blot using speci¢c probes described in Section
2. Sizes of corresponding bands are indicated. B: Quantitation of
the inhibition of tenascin-C gene expression by 1,25-D3. Relative
values of tenascin-C/GAPDH RNA levels with respect to that of
untreated cells were calculated. Mean values corresponding to three
independent experiments are shown. C: Kinetics of inhibition of te-
nascin-C gene expression by 1,25-D3 (100 nM) in serum-free me-
dium. Quantitation of relative values of tenascin-C/GAPDH RNA
levels in 1,25-D3-treated cells with respect to those of their corre-
sponding untreated controls as calculated from Northern blots.
Mean values of two independent experiments are shown.
Fig. 2. Down-regulation of tenascin-C protein by 1,25-D3 in EpH4
cells. Immunoprecipitation of tenascin-C polypeptides expressed in
metabolically labeled EpH4 cells treated or not with the indicated
concentrations of 1,25-D3 for 24 h. The two tenascin-C bands (Mr
240 000 and 220 000) are indicated. Preimmune serum (PIS) was
used as control. Three separate experiments gave the same results.
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3.2. E¡ects of 1,25-D3 on tenascin-C protein synthesis in
EpH4 cells
We used speci¢c anti-tenascin-C antibodies to investigate
whether the reduction in RNA levels correlated with an in-
hibition in tenascin-C protein synthesis. Proteins labeled in
vivo during a 3 h pulse were immunoprecipitated from cells
treated for 24 h with increasing doses of 1,25-D3 or left un-
treated (Fig. 2). Two bands of Mr 240 000 and 220 000 corre-
sponding to tenascin-C polypeptides were detected. Low doses
(10 nM) of 1,25-D3 caused an overall (both bands) inhibition
of tenascin-C protein synthesis of 40%, while at high doses
(100^1000 nM) the inhibition was 65%. These results con-
¢rmed that 1,25-D3 causes a reduction in tenascin-C expres-
sion in EpH4 cells.
3.3. Inhibition of tenascin-C expression by 1,25-D3 in other
mammary epithelial cell lines
Next, we extended the study to other mammary epithelial
cell lines. In at least three additional lines of human (MDA-
MB-231, BT-474) or mouse (HC11) origin which display dif-
ferent phenotypes and express variable levels of tenascin-C,
1,25-D3 also exerted an inhibitory action reducing tenascin-C
RNA levels in a range from 1.9- to 4.4-fold (Fig. 3). We also
studied other cell lines such as MCF-7, T47D and ZR-75
which in agreement with previous reports did not show de-
tectable tenascin-C gene expression ([13], and not shown).
3.4. E¡ect of 1,25-D3 on the inducing activity of serum or
tumor promoters on tenascin-C expression
To further investigate the inhibitory action of 1,25-D3 on
tenascin-C expression, we analyzed whether 1,25-D3 could
block the induction caused either by serum or by the tumor
promoter TPA. To this purpose, EpH4 cells were ¢rst incu-
bated in serum-free medium for 16 h in the presence or ab-
sence of 100 nM 1,25-D3 and then treated for an additional
6 h with either 10% fetal calf serum or 100 nM TPA, alone or
in combination with the same concentrations of 1,25-D3. Con-
trol cells were left in serum-free medium with no additions. To
assess the speci¢city of 1,25-D3 action, estradiol was used in
parallel. As shown in Fig. 4, 1,25-D3 e⁄ciently blunted the
induction of tenascin-C expression caused by either serum or
TPA. In contrast, estradiol had no e¡ect.
4. Discussion
In this study we report the inhibition by 1,25-D3 of tenas-
cin-C expression in a series of mammary epithelial cell lines of
mouse and human origin. Interestingly, this action has been
found in normal, polarized non-tumorigenic cells (EpH4) as
well as in poorly polarized (HC11), in invasive tumorigenic
(BT-474), and also in malignant dedi¡erentiated (MDA-MB-
231) cells. Previously, the molecular basis for the anticancer
activity of 1,25-D3 was proposed to rely on a growth-inhib-
itory action, probably due to the blockade of the cell cycle by
modulating the level of phosphorylation of the retinoblastoma
protein, and on a pro-apoptotic activity [4,8]. Here, we dem-
onstrate that 1,25-D3 causes a rapid inhibition of tenascin-C
expression which is independent of any e¡ect on cell prolifer-
ation or survival. Supporting this, TGF-L induces tenascin-C
in EpH4 cells which is a potent antiproliferative agent in these
cells. Given the relevant roles proposed for tenascin-C pro-
moting cell invasion and angiogenesis, and as an immunosup-
pressor [22], this ¢nding shows that the antitumor activity of
1,25-D3 is more complex than expected, and emphasizes the
rationale of its use as a chemopreventive agent in cancer.
In spite of the proposed role of tenascin-C in mammary
gland morphogenesis, physiology, and tumorigenesis, very lit-
tle is known about its regulation in mammary epithelial cells.
In HC11 cells tenascin-C has been found to be up-regulated
by TGF-L and down-regulated by epidermal growth factor
[14]. In addition, a down-regulation of tenascin-C expression
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Fig. 3. Inhibition of tenascin-C mRNA levels by 1,25-D3 in a varie-
ty of mammary epithelial cell lines. Poly(A) RNA (10 Wg/lane) ex-
tracted from the indicated cell lines treated or not with 1,25-D3
(100 nM) for 24 h in serum-free medium was hybridized to speci¢c
probes. Sizes of the corresponding bands are indicated. Lower num-
bers represent the fold inhibition in tenascin-C mRNA levels caused
by 1,25-D3 treatment after normalization versus GAPDH mRNA
levels.
Fig. 4. 1,25-D3 inhibits the increase of tenascin-C mRNA levels
by TPA or FCS. A: EpH4 cells were treated with 1,25-D3 (100
nM), estradiol (E2, 100 nM) or left untreated for 16 h in serum-free
medium. As indicated, TPA (100 nM) or FCS (10%) was then
added for an additional 6 h. Poly(A) RNA (10 Wg/lane) was ana-
lyzed by Northern blot. B: Quantitation of the interference of 1,25-
D3 with the inducing activity of TPA and FCS on tenascin-C ex-
pression. Statistical analysis of the data obtained in three independ-
ent experiments; mean þ S.D. Statistical signi¢cance: **P6 0.01;
***P6 0.001.
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by antiprogestins has been reported in rat mammary tumors
[23]. Studies carried out with di¡erent cell types such as ¢bro-
blasts, vascular smooth muscle, astrocytes or bone marrow
stromal cells in which tenascin-C is regulated by di¡erent
growth factors, cytokines, and steroids have shown that the
regulation of tenascin-C expression is cell-speci¢c [24]. The
analysis of the promoter region of the chicken and human
tenascin-C genes has not yet given much information about
possible transcriptional regulators [24]. Recently, the dissec-
tion of the mouse tenascin-C promoter has revealed the exist-
ence of multiple elements for a series of transcription factors
(Krox-24, Brn-2, NF-1, and POU factors) which function in a
complex, cell-speci¢c fashion [25].
Our results suggest a direct e¡ect of 1,25-D3 on tenascin-C
gene expression which may play a role in the physiological
regulation of the gene. This e¡ect seems to be mostly at the
level of mRNA stability. In addition, the blockade of the
induction of tenascin-C by serum or TPA supports the idea
that 1,25-D3 may act also by inhibiting the AP-1-dependent
expression of this gene.
Given the relevant activities proposed for tenascin-C in tu-
morigenesis, particularly in breast malignancies, the inhibitory
e¡ect described here most probably contributes to the antitu-
mor activity of 1,25-D3.
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